Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 10Carcinoma, Non-Small-Cell Lung 10Carcinoma, Hepatocellular 8Lung Neoplasms 6Colorectal Neoplasms 6Neoplasms 5Prostatic Neoplasms 4Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Solid Tumors 2Small Cell Lung Cancer Extensive Stage 2Sarcoma, Alveolar Soft Part 2Sarcoma 2Ovarian Neoplasms 2Mesothelioma, Malignant 2Melanoma 2Liver Neoplasms 2Extensive Stage Lung Small Cell Carcinoma 2Carcinoma, Renal Cell 2Carcinoma 2Wilms Tumor 1Vulvar Neoplasms 1Vaccinia 1Sarcoma, Clear Cell 1Rhabdomyosarcoma 1Papillary renal cell carcinoma, sporadic 1PIK3CA-Mutated Cancers 1Osteosarcoma 1

Interventions

dehydroftorafur 1atezolizumab 1Specimen Handling 1Restraint, Physical 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
DNA Repair-Deficiency Disorders × atezolizumab × 30 days × Clear all
NCT02912559 2026-06-01

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

National Cancer Institute (NCI)

Phase 3 Active not recruiting
712 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, DNA Repair-Deficiency Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡